Vindesine in the treatment of advanced colorectal cancer: a phase II study

Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials.

Clinical colorectal cancer·2023

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.

ESMO open·2021

Treatment patterns for metastatic colorectal cancer in Spain.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2020

The burden of cancer in Spain.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2018

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.

European journal of cancer (Oxford, England : 1990)·2018

Hyperprogression as a distinct outcome after immunotherapy.

Cancer treatment reviews·2018

Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma.

Cancer treatment reports·1987

IV melphalan in children.

Cancer treatment reports·1987

Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.

Cancer treatment reports·1987

Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.

Cancer treatment reports·1987

Doxorubicin distribution in human breast cancer.

Cancer treatment reports·1987

Phase I study of echinomycin.

Cancer treatment reports·1987

From Phase Ib/II to Seamless Phase II/III: A Simulation-Based Discussion of Design Strategies for Dose Optimization and Confirmatory Phase.

Clinical pharmacology and therapeutics·2026

INSR Armoring Protects CAR-NK and CAR-T Cells Against Tumor Stroma-Induced CAR Shedding by Maintaining Cholesterol Homeostasis.

Cancer research·2026

Matching-adjusted indirect treatment comparisons in chronic inflammatory demyelinating polyneuropathy: interpreting current evidence and enhancing future studies.

Journal of comparative effectiveness research·2026

Epidemiology of medication-related problems and antimicrobial utilisation among critically ill cancer patients: Determinants, pharmacist interventions and clinical outcomes-A prospective observational study.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Enhancing Cancer Immunotherapy with Berberine and Its Loaded Nanoparticles: A Systematic Review.

Anti-cancer agents in medicinal chemistry·2026

Magnetic and Non-Magnetic Halloysite Nanotubes Functionalized with Folic Acid for the Targeted Delivery of [Pd(dipic)Cl].H2O: Cytotoxicity and Apoptosis Induction in Colon Cancer Cells.

Anti-cancer agents in medicinal chemistry·2026

Related Experiment Videos

Vindesine in the treatment of advanced colorectal cancer: a phase II study

Related Concept Videos

Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials.

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.

Treatment patterns for metastatic colorectal cancer in Spain.

The burden of cancer in Spain.

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.

Hyperprogression as a distinct outcome after immunotherapy.

Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma.

IV melphalan in children.

Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.

Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.

Doxorubicin distribution in human breast cancer.

Phase I study of echinomycin.

From Phase Ib/II to Seamless Phase II/III: A Simulation-Based Discussion of Design Strategies for Dose Optimization and Confirmatory Phase.

INSR Armoring Protects CAR-NK and CAR-T Cells Against Tumor Stroma-Induced CAR Shedding by Maintaining Cholesterol Homeostasis.

Matching-adjusted indirect treatment comparisons in chronic inflammatory demyelinating polyneuropathy: interpreting current evidence and enhancing future studies.

Epidemiology of medication-related problems and antimicrobial utilisation among critically ill cancer patients: Determinants, pharmacist interventions and clinical outcomes-A prospective observational study.

Enhancing Cancer Immunotherapy with Berberine and Its Loaded Nanoparticles: A Systematic Review.

Magnetic and Non-Magnetic Halloysite Nanotubes Functionalized with Folic Acid for the Targeted Delivery of [Pd(dipic)Cl].H2O: Cytotoxicity and Apoptosis Induction in Colon Cancer Cells.

Related Experiment Videos

Vindesine in the treatment of advanced colorectal cancer: a phase II study

Related Concept Videos

Related Articles